Free Newsletter
Facing state barriers, flu jabs go unused
Years ago, it was typical to have flu vaccine shortages as doctors would typically use up their supply early in the season. Those long lines are history; vaccine production is at an all-time high. According to the CDC, suppliers have created 146 million units this year. And now it's the flu vaccines themselves that are waiting to be used. State regulations requiring prescriptions for flu shots may keep many from getting immunized and leave millions of vaccines unused. As many as 20 million units may be disposed of this year.
Among the states that require a prescription or a license nurse or physician to administer the jab are Arizona, South Carolina, and Maine, as well as the District of Columbia. In September, Georgia became the last state to adopt this policy. The change in policy came after a legal ruling regarding a complaint filed with the state Board of Pharmacy last year. The flu vax is now considered a "dangerous drug" in Georgia and as such, cannot be administered by a pharmacist without a prescription.
Sanofi Pasteur supplies 50 percent of vaccines to healthcare providers across the country. As flu strains change, the vaccine must be re-created each year. As a result, the company expects to see losses because of the large amount of unused vaccines this flu season.
- check out ABCNews for more
Related Articles:
VaxInnate in a race to produce 'universal' flu vaccine
Breakthrough on influenza vaccine
Flu research points to new delivery technique
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




